Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
MBP-PLP fusion protein (MP4)-induced experimental autoimmune encephalomyelitis (EAE) is a model for multiple sclerosis (MS) that encompasses both a time-dependent attack on central nervous system (CNS) regions and a B cell component, mirroring important features of human multiple sclerosis.
|
20078558 |
2009 |
Encephalomyelitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We assessed EAE-related parameters, detected pathological changes with immunohistochemistry and quantified the expression of myelin basic protein (MBP), matrix metalloproteinase-9 (MMP-9), and a subset of EAE-related cytokines using enzyme-linked immunosorbent assay (ELISA).
|
23525227 |
2013 |
Encephalomyelitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
DAB(389)IL-2 in vitro treatment suppressed cytotoxicity of MBP-activated T cells from rats with EAE against oligodendrocytes in culture by 66%.
|
23872438 |
2014 |
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, Lewis rats immunized with myelin basic protein (MBP) 82-99 or MBP68-86 exhibited clinical signs of EAE and inflammatory infiltrates throughout CNS.
|
24388990 |
2014 |
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using this approach, we demonstrate that antigen persistence is a dominant factor governing the elicitation of tolerance in the model of multiple sclerosis (MS), experimental autoimmune encephalomyelitis (EAE), induced by immunizing B10.PL mice with the N-terminal epitope of myelin basic protein.
|
27236506 |
2016 |
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
DHEA-S treatment also preserved myelin basic protein immunoreactivity and reduced axonal loss in animals with EAE, relative to vehicle-treated EAE animals.
|
28707358 |
2017 |
Encephalomyelitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Consistently, histopathological studies coupled with microscope-cellSens quantification and RT-qPCR analyzes showed that XBD173 prevented demyelination by restoring normal protein and mRNA levels of myelin basic protein that was significantly repressed in PLP-EAE mice spinal cord and brain.
|
28899788 |
2017 |
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we demonstrated that subcutaneously administered myelin basic protein (MBP)-pulsed CD11c+ bone marrow-derived dendritic cells (BMDC) were as effective at inducing EAE as subcutaneously administered MBP plus CFA.
|
27488372 |
2017 |
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Development and Pre-Clinical Evaluation of Recombinant Human Myelin Basic Protein Nano Therapeutic Vaccine in Experimental Autoimmune Encephalomyelitis Mice Animal Model.
|
28425447 |
2017 |
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, immunodominant MBP peptides encapsulated into the mannosylated liposomes, referred as Xemys, were shown to suppress development of experimental autoimmune encephalomyelitis, a rodent model of MS, and furthermore passed the initial stage of clinical trials.
|
29085375 |
2017 |
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Male Lewis rats were immunized with myelin basic protein (MBP) peptide to establish an EAE model and then treated with three doses of PZH.
|
29682587 |
2018 |
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since histone deacetylase (HDAC) inhibitors have been previously shown to improve neurological disability, we also show that treatment with trichostatin A (a HDAC inhibitor) improves the NDS of EAE mice but does not change MBP acetylation.
|
29111742 |
2018 |
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
During the acute EAE phase (7-20 days after immunization), catalytic antibodies efficiently hydrolysing myelin basic protein (MBP), MOG and DNA are produced with parallel suppression of antibodies hydrolysing histones.
|
30265424 |
2018 |
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A myelin basic protein (MBP)-induced experimental allergic encephalomyelitis (EAE) involves paraplegia due to a reversible thoracolumbar spinal cord impairment.
|
29224959 |
2018 |
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aspirin reduced the development of EAE driven by myelin basic protein (MBP)-specific T cells and the associated perivascular cuffing, inflammation, and demyelination.
|
30482850 |
2018 |
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In particular, cyclo(87-99)[Arg<sup>91</sup>, Ala<sup>96</sup>]MBP<sub>87-99</sub> was highly effective in preventing the onset and development of clinical symptoms and spinal cord pathology and providing lasting protection against EAE induction.
|
29385090 |
2018 |
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previously, we showed that myelin-reactive autoantibodies from patients with multiple sclerosis (MS) and mice with experimental autoimmune encephalomyelitis (EAE) exhibit the ability to recognize and hydrolyse distinct epitopes within myelin basic protein (MBP).
|
30139963 |
2018 |
Encephalomyelitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results showed: (1) diverse pathological features of long-term relapsing-remitting EAE; (2) relatively increased MBP and reduced β-APP expression in LA recipients 180 days after onset; (3) down-regulated TNF-α and up-regulated TGF-β levels in LA recipients 7 days after onset; (4) lower MDA and higher SOD levels in LA recipients 180 days after onset; (5) increased Treg levels in LA recipients 7 days after onset.
|
30338822 |
2018 |
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myelin basic protein (MBP) is a major target of T cells in lesions of multiple sclerosis (MS) patients and its animal model, experimental autoimmune encephalomyelitis (EAE).
|
28889362 |
2018 |
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study was designed to investigate the role of calpain and the proteasome in the removal of oxidized neuronal cytoskeletal proteins in myelin basic protein-induced experimental autoimmune encephalomyelitis (EAE).
|
30251207 |
2018 |
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used myelin basic protein (MBP)-proteolipid protein (PLP)-induced experimental autoimmune encephalomyelitis (EAE) in C57BL/6 (B6) mice as B cell-dependent model of MS. Mice were treated intraperitoneally either at the peak of EAE or at 60 days after onset with 200 μg murine anti-CD52 vs. IgG2a isotype control antibody for five consecutive days.
|
30098594 |
2018 |
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, the magnitudes of myelin basic protein (MBP)-induced rise in the frequency of IFN-γ+ and IL-17+ CD8+ T cells (providing important help to neuroantigen-specific CD4+ T cells in EAE models characterized by clinically mild disease) were greater in dLN cell cultures from aged AO rats.
|
29128575 |
2018 |
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We then monitored the thickness of the retinal layers in different EAE models: in wild-type (WT) C57Bl/6J mice immunized with myelin oligodendrocyte glycoprotein peptide (MOG<sub>35-55</sub>) or with bovine myelin basic protein (MBP), in TCR<sup>2D2</sup> mice immunized with MOG<sub>35-55</sub>, and in SJL/J mice immunized with myelin proteolipid lipoprotein (PLP<sub>139-151</sub>).
|
31684959 |
2019 |
Encephalomyelitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Induction of EAE caused a significant decrease of myelin basic protein expression in the hindbrain of disease affected WT mice in comparison to Cpt1a P479L mice.
|
31527712 |
2019 |
Encephalomyelitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrated that immunisation with a high dose of myelin basic protein (MBP) peptide and complete Freund's adjuvant failed to effectively initiate EAE, in contrast to low dose MBP peptide immunisation which readily induced disease.
|
30485411 |
2019 |